בליאומיצין PFI

Country: Израел

Језик: Хебрејски

Извор: Ministry of Health

Активни састојак:

BLEOMYCIN SULFATE

Доступно од:

MEGAPHARM LTD

АТЦ код:

L01DC01

Фармацеутски облик:

אבקה להכנת תמיסה לזריקה

Састав:

BLEOMYCIN SULFATE 15000 IU/VIAL

Пут администрације:

לתוך קרום הריאה, תוך-עורקי, תוך-ורידי, תת-עורי, תוך-שרירי, לתוך בקע

Тип рецептора:

מרשם נדרש

Произведен од:

BAXTER ONCOLOGY GmbH, GERMANY

Терапеутска група:

BLEOMYCIN

Терапеутска област:

BLEOMYCIN

Терапеутске индикације:

Bleomycin is useful in the management of the following neoplasms: Squamous cell carcinoma affecting the mouth, nasopharynx and paranasal sinuses, larynx, oesaphagus, cervix, vagina, penis and skin. Well differentiated tumors usually respond better than anaplastic ones.Hodgkin's disease and other malignant lymphomas, including mycosis fungoides. Testicular carcinoma (seminoma and no seminoma) .Malignant effusions of serous cavities (intrapleural and intraperitoneal).Secondary indications in which bleomycin has been shown to be of some value include metastatic malignant melanoma, carcinoma of the thyroid lung and bladder. Local treatment of refractory warts. Bleomycin can be used as a single agent, but is generally used in combination with other cytotoxics and/or with radiation therapy.

Датум одобрења:

2020-09-30